Nathaniel Bradley
About Nathaniel Bradley
Nathaniel Bradley, age 49, has served as Chief Executive Officer and a director of Datavault AI Inc. since December 31, 2024; he holds bachelor’s degrees in business administration and marketing from the University of Phoenix and has prior CTO and CEO experience across IP, healthcare, blockchain, cybersecurity, AI and data science domains . Under his tenure, Datavault reported accelerating revenue: Q2 2025 recognized revenue of $1.7M (up 467% YoY) and Q3 2025 revenue of $2.904M versus $1.172M in Q3 2024, while pursuing IP commercialization and platform launches . EBITDA and TSR were not disclosed.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| EOS Technology Holdings Inc. | CEO and sole director | Oct 2018 – Present | Led IP and technology assets that were acquired by DVLT; remains related party with earnout economics |
| Intellectual Property Network, Inc. | CEO | Jan 2008 – Present | IP commercialization across web and data valuation domains |
| Parallax Health Sciences, Inc. | Chief Technology Officer | 2018 – 2021 | Technology leadership in healthcare |
External Roles
| Organization | Role | Board/Committee | Notes |
|---|---|---|---|
| EOS Technology Holdings Inc. | CEO and sole director | Board | Control person; EOS is a DVLT related party |
| Public company boards | — | — | No other public company directorships |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus (%) | Actual Bonus ($) | Notes |
|---|---|---|---|---|
| 2024 | — | — | — | Bradley became CEO on Dec 31, 2024; no 2024 compensation reported |
Performance Compensation
| Grant/Plan | Metric | Weighting | Target | Actual/Payout | Vesting |
|---|---|---|---|---|---|
| Inducement RSUs (500,000) | Time-based | 100% of tranche | — | — | Vests in equal three-month installments over 36 months beginning Dec 20, 2025 |
| Inducement RSUs (600,000) | Performance-based conditions (not specified) | 100% of tranche | Not disclosed | Not disclosed | Performance-based vesting; conditions not detailed |
Equity Ownership & Alignment
| Holder | Shares | % of Outstanding | Detail |
|---|---|---|---|
| Nathaniel Bradley (beneficial ownership) | 19,700,790 | 7.0% | Includes 4,235,970 directly owned, 12,289,002 held by EOS (Bradley is CEO and sole director), and 3,175,818 held by spouse |
| Vested vs Unvested | Not disclosed | — | Outstanding RSUs for Bradley total 1,100,000; all unvested as of Oct 14, 2025 |
| Options/warrants | None for Bradley | — | No options reported in “Outstanding Equity Awards as of Dec 31, 2024” |
| Hedging/Pledging | Hedging prohibited | — | Company prohibits insider hedging; pledging not disclosed |
Employment Terms
| Term | Provision |
|---|---|
| Start date & role | CEO and director since Dec 31, 2024 |
| Employment agreement | Not disclosed for Bradley in proxy; 2024 compensation reported as nil |
| Severance / Change-of-control | Not disclosed for Bradley (Moyer’s terms disclosed separately) |
| Lock-up / Selling constraints | Directors and executive officers agreed to lock-up until the Additional Closing Date tied to Scilex transaction |
Board Governance
- Independence: Bradley is not independent; Board majority independent (Briskey, Gilbert, Peruvemba, Tobias, Wilson) .
- Leadership: Bradley is CEO; Brett Moyer is Chairman of the Board .
- Committees (Bradley not listed as member):
- Audit: Briskey (Chair, Financial Expert), Peruvemba, Wilson .
- Compensation: Peruvemba (Chair), Gilbert, Tobias; no independent compensation consultant used .
- Nominating & Corporate Governance: Tobias (Chair), Gilbert .
- Board meetings/attendance: 4 meetings in 2024; no incumbent director attended fewer than 75% .
- Lead Independent Director: None .
Director Compensation (context for board service)
| Director (2024) | Cash Fees ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| Gilbert | 20,000 | 44,090 | 64,090 |
| Howitt | 20,000 | 44,090 | 64,090 |
| Kristensen | 20,000 | 44,090 | 64,090 |
| Peruvemba | 20,000 | 44,090 | 64,090 |
| Tobias | 20,000 | 44,090 | 64,090 |
| Wilson | 20,000 | 44,090 | 64,090 |
| Briskey | 15,000 | 31,903 | 46,903 |
Performance & Track Record
- Revenue momentum: Q2 2025 recognized revenue of $1.7M; booked $2.5M patent licensing with NYIAX; targeting $25M run-rate by year-end and $40–50M revenue in 2026 .
- Q3 2025: Revenue $2.904M vs $1.172M prior year; nine-month revenue $5.268M vs $1.772M prior year .
- Strategic initiatives: IBM watsonx AI agent commercialization, elements/NIL/politics exchanges, acquisitions in Acoustic and Data divisions, CSI asset purchase integration .
- Balance sheet/IP build: Intangible assets $97.548M; goodwill $19.135M; patents/trademarks amortization schedules established .
Company performance snapshot
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Revenue ($000s) | 1,172 | 2,904 |
| Net Loss ($000s) | (5,092) | (32,976) |
Revenue progression
| Metric | Q2 2024 | Q2 2025 |
|---|---|---|
| Recognized Revenue ($000s) | ~300 | 1,700 |
Related Party Transactions (Governance red flags)
- EOS Note and conversion: DVLT owed $10.0M under EOS note at 12/31/24; $8.3M balance as of 6/30/25; EOS converted $3.2M into 10,000,000 common shares at $0.32 on Sept 7, 2025; Bradley is a control person of EOS, and his spouse is EOS CMO (also DVLT CMO) .
- Transition Services: DVLT paid EOS $428,000 (Q1 2025) and $501,000 (H1 2025); $97,000 due at 6/30/25 .
- Updated DV Note: DV Convertible Note fair value $4.5M at 9/30/25 after repayments and conversion activity .
- Hansong transactions (director-related): Purchases/sales, payables/receivables activity detailed; immaterial ownership (<1%) .
Risk Indicators & Red Flags
- Going concern: Substantial doubt remains; cash $1.683M at 9/30/25; net cash used in operations $23.204M YTD; requires additional funding within 12 months .
- Dilution overhang: Share increase proposal to 2.0B common; Pre-Funded Warrant to Scilex exercisable for 263,914,094 shares at $0.0001; potential change-of-control implications under Nasdaq rules .
- Convertible notes: 2025 and Q3 2025 notes with low floor prices and cash redemption rights; fair value losses recognized; asset liens; senior ranking and investor participation rights .
- Hedging prohibition: Insiders barred from hedging transactions; reduces alignment risk from derivatives .
- Legal proceedings disclosed: No adverse findings for Bradley; historical items noted for other officers/directors (e.g., receivership/ABCs) .
Compensation Committee Analysis
- Composition: All independent (Peruvemba Chair, Gilbert, Tobias) .
- Consultant use: No independent compensation consultant retained .
- Executive participation: Prior CEO (Moyer) provided recommendations but did not set his own pay; process formalized via charter .
Equity Ownership & Vesting Pressure Timeline
| Instrument | Amount | Key dates | Potential selling pressure |
|---|---|---|---|
| Common shares (beneficial) | 19,700,790 | Ongoing | Subject to standard insider trading windows and lock-up until Additional Closing |
| RSUs (time-based) | 500,000 | Begin vesting Dec 20, 2025; quarterly for 36 months | Quarterly releases could add supply; mitigated by lock-up constraints near-term |
| RSUs (performance-based) | 600,000 | Not disclosed | Dependent on undisclosed KPIs |
| Options | None | — | No option-related pressure |
Employment & Contracts (Retention/Transition)
- Bradley’s specific employment contract terms, severance multiples, and change-of-control triggers are not disclosed in the proxy; only 2024 compensation is reported as nil following appointment at year-end .
- Lock-up agreements and Scilex voting agreements limit near-term disposals and align governance for share authorization and transaction approvals .
Board Service History & Dual-Role Implications
- Board service: Director since December 2024 .
- Committee roles: None listed for Bradley; committees composed of independent directors .
- Dual-role considerations: CEO plus director with a non-independent chairman (Moyer); no Lead Independent Director—heightens need for robust independent committees and oversight of related-party transactions (EOS) .
Investment Implications
- Alignment: Significant beneficial ownership (7.0%) via direct, EOS-controlled, and spouse holdings indicates skin-in-the-game; RSU structure blends time- and performance-based vesting but performance metrics are undisclosed .
- Liquidity and dilution risk: Going concern disclosures, senior convertible notes, and very large authorized share increase create dilution and financing overhangs that can drive volatility and trading signals; Scilex warrant/board rights could be a governance overhang if exercised .
- Execution vs. red flags: Revenue growth is accelerating with platform/IP strategy and CSI integration, but heavy fair value losses on financing instruments, reliance on related-party EOS agreements, and absence of disclosed CEO employment economics increase governance and retention risk .
- Near-term selling pressure: Lock-up through Additional Closing and lack of options temper immediate pressure; quarterly RSU vesting starting Dec 20, 2025 introduces structured supply thereafter .